Ticker Details
Intellia Therapeutics, Inc. Intellia Therapeutics Inc is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as the CRISPR/Cas9 system.
IPO Date:	May 6, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.16B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.19 | 3.58%
Avg Daily Range (30 D):	$0.54 | 3.78%
Avg Daily Range (90 D):	$0.54 | 3.82%

Institutional Daily Volume
Avg Daily Volume:	1.44M
Avg Daily Volume (30 D):	5.16M
Avg Daily Volume (90 D):	5.14M

Trade Size
Avg Trade Size (Sh.):	81
Avg Trade Size (Sh.) (30 D):	93
Avg Trade Size (Sh.) (90 D):	94

Institutional Trades
Total Institutional Trades:	5,163
Avg Institutional Trade:	$2.98M
Avg Institutional Trade (30 D):	$4.71M
Avg Institutional Trade (90 D):	$3.65M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$4.99M
Avg Closing Trade (30 D):	$11.98M
Avg Closing Trade (90 D):	$8.49M
Avg Closing Volume:	182.09K

News

Jul 3, 2026 @ 8:44 AM Gene Editing Therapeutics: Transforming Biopharmac... Source: Researchandmarkets.Com

Jul 3, 2026 @ 8:41 AM Global CRISPR-Based Drug Development Platforms Mar... Source: Researchandmarkets.Com

Jun 24, 2026 @ 8:03 AM Wall Street Expects This Growth Stock That's Alrea... Source: Adria Cimino

Jun 20, 2026 @ 3:02 PM Intellia Therapeutics vs. Omeros: Which Emerging B... Source: Brendan Coffey

Jun 17, 2026 @ 6:30 AM This Stock Is Up 58% This Year. Is It too Late to ... Source: Prosper Junior Bakiny

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-.81	$-.82	$-3.81
Diluted EPS	$-.81	$-.82	$-3.81
Revenue	$15.05M	$23.02M	$67.67M
Gross Profit
Net Income / Loss	$-96.23M	$-95.79M	$-412.69M
Operating Income / Loss	$-100.53M	$-98.71M	$-440.99M
Cost of Revenue
Net Cash Flow	$-17.47M	$-39.77M	$-35.22M
PE Ratio